Ardelyx, Inc. Announces Appointment of Susan Rodriguez as First Chief Commercial Officer
May 18, 2020 at 04:01 pm EDT
Share
Ardelyx, Inc. announced the appointment of Susan Rodriguezas the company's first chief commercial officer. Ms. Rodriguez will be responsible for leading the commercial organization, including launch planning and strategy, as well as alliance management and business development. Ms. Rodriguez is a seasoned healthcare executive with extensive leadership experience across pharmaceutical, biopharma, hospital products, and nutrition segments in U.S. and international markets. Previously, Ms. Rodriguez served as the founding chief executive officer of Tolmar Pharmaceuticals. Prior to Tolmar, Ms. Rodriguez held various positions at Abbott Laboratories, most recently divisional vice president of global marketing, establishing a global marketing function for a $3.8 billion international portfolio of nutrition brands.
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.